NDAORALTABLET, ORALLY DISINTEGRATINGPriority Review
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
13
Data completeness
7/8 — Comprehensive
Priority Review
NURTEC ODT (rimegepant sulfate) by Pfizer is gene-related peptide receptor antagonist. Approved for migraine. First approved in 2020.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NURTEC ODT (rimegepant sulfate) is an orally disintegrating tablet developed by Pfizer for the acute treatment of migraine in adults. It is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that works by blocking CGRP signaling, a key pathway in migraine pathophysiology. Approved by the FDA on February 27, 2020, NURTEC ODT offers a rapid-onset, non-triptan alternative for migraine sufferers seeking symptom relief without cardiovascular contraindications.
$0.5BPart D
12.9 years to LOEMechanism of Action
gene-related peptide receptor antagonist.
Indications (1)
Clinical Trials (13)
A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea
Started Oct 2026
3,000 enrolled
Migraine With or Without Aura
Consistency of Response With Rimegepant in Acute Treatment of Migraine
Started Nov 2025
250 enrolled
Migraine
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
Started Sep 2025
60 enrolled
MigraineTrigger Induced Migraine
Acute Migraine Treatment in the ED With Gepants
Started Jun 2025
9 enrolled
Migraine Headaches
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
Started Oct 2024
1,395 enrolled
Migraine
Worked on NURTEC ODT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.